Shire gets extended Marketing Authorisation for Revestive
The European Commission has granted an extension of the Market Authorisation for Shire’s Revestive (teduglutide) 5 mg powder and solvent for injection for the treatment of patients aged one year and above with Short Bowel Syndrome (SBS).
Click on this link for more information.
